What is Vivitrol and how is it different from Suboxone?
Vivitrol is extended-release naltrexone — an opioid antagonist that blocks opioid receptors entirely, while Suboxone (buprenorphine) is a partial agonist that activates them. The mechanisms are opposite, and the clinical profiles differ accordingly.
Vivitrol does not relieve withdrawal symptoms, does not produce any opioid effect, and cannot be misused. A patient who uses heroin or fentanyl while on Vivitrol will feel nothing — the receptor is occupied by naltrexone. Suboxone, in contrast, suppresses withdrawal and cravings through partial receptor activation and requires careful tapering when discontinued.
The trade-off: Vivitrol requires the patient to be fully detoxed before the first dose. The FDA approved Vivitrol for opioid use disorder in 2010 and for alcohol use disorder in 2006.
Who is a good candidate for Vivitrol injection?
Vivitrol is most effective for motivated patients who have completed detox, have stable housing and accountability structures, and prefer an antagonist over an agonist. NIDA-funded research (Lee et al., NEJM 2011) demonstrated a 90% reduction in opioid use versus placebo among adults with opioid use disorder receiving monthly naltrexone.
Strong candidates include patients leaving inpatient detox or residential treatment, individuals with alcohol use disorder seeking to reduce heavy drinking days, professionals with licensure or employment monitoring requirements, and those for whom a daily medication is impractical.
Vivitrol is contraindicated in patients with current opioid dependence (without prior detox), acute hepatitis, or hepatic failure. A naloxone challenge or 7–14 day abstinence period precedes the first injection.
Questions About Who is a good?
Call our 24/7 admissions line or verify your insurance online.
How does the monthly injection schedule work?
Vivitrol is administered as a single 380 mg intramuscular injection into the gluteal muscle once every 4 weeks. The extended-release microsphere formulation delivers therapeutic naltrexone levels for approximately 28–30 days, eliminating the daily adherence burden of oral naltrexone.
The first injection follows a documented 7–14 day opioid-free period, confirmed by negative urine drug screen and often a naloxone challenge. Subsequent injections occur every 4 weeks, scheduled into the client's PHP, IOP, or outpatient visit cadence.
- Pre-injection check: Drug screen, hepatic function review, side effect assessment.
- Injection: Administered by licensed clinical staff in office.
- Post-injection: 30-minute observation window, side effect education, next-dose scheduling.
“Vivitrol gives motivated patients a 28-day window where the drug simply cannot work. That window is where the real treatment happens — therapy, skills, family repair, and life rebuilding. The medication clears the path; the work fills it.”
What clinical support does Vivitrol require?
Vivitrol works best as one component of a comprehensive treatment plan that includes CBT, trauma therapy, group programming, and structured accountability. The medication blocks the reward circuit, but the underlying drivers of addiction — trauma, cognitive distortions, environmental triggers, dual diagnosis — require behavioral treatment.
Ascend integrates Vivitrol into PHP, IOP, and outpatient programming with weekly to multi-weekly individual therapy, daily or near-daily group therapy in PHP and IOP, psychiatric medication management for co-occurring conditions, and family education on the medication and recovery process.
SAMHSA TIP 63 emphasizes that medication without behavioral treatment produces inferior outcomes compared to integrated care across all three FDA-approved MAT options.